NTT Research partners with TUM on technologies to advance patient care
By Akshay Kedari  Date: 2019-11-13

NTT Research partners with TUM on technologies to advance patient care

NTT Research, Inc., has recently unveiled that its Medical and Health Informatics (MEI) Lab has signed a joint research agreement with the Technical University of Munich to work on three-dimensionally implantable and transformable electrodes.

A renowned medical researcher and scientist and director of the MEI Lab, Dr. Hitonobu Tomoike (M.D., Ph.D.) will be teamed up with Professor of Neuroelectronics, Dr. Bernhard Wolfrum at TUM in the Munich School of BioEngineering. The major scope of work for this multi-year project involves assembling 3D structures, screening and improving functional materials, and assessing biocompatibility.

Apparently, the NTT Research MEI Lab focuses on the miniaturization and transformation of medical device components. This mutual research will focus on the tendency of traditional electronics to work against and at a comparative distance from, instead of with and alongside the targeted organ or tissue.

The flexible micro- or nano-scale electrodes envisaged as a result of this project are anticipated to minimize the adverse impact that severe and planar electrode materials have on smooth and curvilinear biological samples.

According to Dr. Tomoike, with the aim to procure in-vivo biological signals stably and with a high-level accuracy for a longer time, a flexible electrode with higher biocompatibility is required. To attain this, the company will make use of micro-scale and nano conductive polymer thin films that are affable to living bodies and consider the use of in vivo implant electrodes, and also the control of structural change of the functional electrodes in the body.

Sources mentioned that this agreement also expands the goal of NTT Research of connecting with partners across the world. The MEI Lab is also planning to open an office in Germany. In the course of this project, MEI Lab will also send its two researchers to Munich. The research will formally launch in Q1 of 2020 and the first phase of the project may possibly take more than two years.
 

Source Credits: https://www.businesswire.com/news/home/20191112005536/en/NTT-Research-Technical-University-Munich-TUM-Enter

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...